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Abstract
Background: Fractional flow reserve (FFR) assesses a functional impact of the atheroma on the 
myocardial ischemia, but it does not take into account the morphology of the lesion. Previous optical 
coherence tomography (OCT), intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) 
studies presented their potential to detect vulnerable plaques, which is not possible by FFR assessment. 
With the following study, the intermediate lesions were assessed by FFR, OCT and combined NIRS-
IVUS imaging to identify plaque vulnerability. 
Methods: Thirteen intermediate lesions were analyzed simultaneously by FFR, OCT and combined 
NIRS-IVUS imaging. 
Results: Two lesions were found to have FFR ≤ 0.80 (0.65 and 0.76). The other 11 lesions had FFR 
> 0.80 with a mean FFR 0.88 ± 0.049. Two lesions with FFR ≤ 0.80 had plaque burden (PB) > 70%  
and minimal lumen area (MLA) < 4 mm2, but neither  of these 2 lesions were identified as OCT de-
fined thin fibrous cap atheroma (TCFA), or NIRS-IVUS possible TCFA. Among the other 11 lesions 
with FFR > 0.80, 8 were identified as OCT-defined TCFA, 4 had PB > 70%, 6 had MLA < 4 mm2,  
2 had both PB > 70% and MLA < 4 mm2, 3 lesions were identified as NIRS-IVUS possible TCFA, 
and 4 lesions had lipid core burden index > 400.
Conclusions: The FFR-negative lesions pose traits of vulnerability as assessed simultaneously by 
IVUS, OCT and NIRS imaging. (Cardiol J 2018; 25, 2: 196–202)
Key words: vulnerable plaque, fractional flow reserve, optical coherence tomography, 
near-infrared spectroscopy, intravascular ultrasound
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Introduction
Fractional flow reverse (FFR) estimation be-
came a standard in the assessment of intermediate 
lesions. The value of FFR ≤ 0.80 became a cut-off 
value to intervene, and such an approach was well 
documented to reduce the incidences of future 
major adverse cardiac events (MACE) [1]. 
Fractional flow reverse assesses a functional 
impact of atheroma on the myocardial ischemia, 
but  does not take into account the morphology of 
the lesion. Previous histological and intravascular 
imaging studies identified features of vulnerable 
plaques, which are prone to rupture. Post-mortem 
studies presented that thin fibrous cap atheroma 
(TCFA) covered rupture plaques [2] and in vivo 
optical coherence tomography (OCT) identified 
TCFA more frequently in ST elevation myocardial 
infarction (STEMI) patients [3]. The prospect study 
presented that lesions with plaque burden (PB) 
≥ 70% and minimal lumen area (MLA) ≤ 4 mm2 
on intravascular ultrasound (IVUS) imaging in-
creased the risk of MACE [4]. A high lipid burden 
assessed by  intravascular near-infrared spectros-
copy (NIRS) suggested increased the risk of future 
MACE [5], and combined NIRS-IVUS imaging 
study presented its potential to detect TCFA [6].
Given the results of histological and intravas-
cular imaging, the question arose whether FFR 
assessment was sufficient to exclude intermedi-
ate lesions from  intervention. With the following 
study, the intermediate lesion was assessed by 
the simultaneous OCT and combined NIRS-IVUS 
imaging together with FFR assessment. The aim 
of this study was to describe intermediate lesion 
characteristics in regard to their vulnerability and 
FFR results.
Methods
Study population
The current study employed intravascular 
FFR, OCT and combined NIRS-IVUS assessment 
of identical coronary intermediate lesions of the 
same patient. All imaging was performed during 
the same procedure. The study group was selected 
from patients referred for cardiac catheterization 
due to chronic stable coronary disease symptoms. 
Patients with renal failure (creatinine > 1.5 mg/dL), 
hemodynamic compromise, contrast allergy, aorto-
ostial coronary artery lesions, and calcified lesions 
were excluded from the study. Intermediate lesions 
to assess by FFR were selected at the operator’s 
discretion after the diagnostic angiogram. FFR, 
OCT, and NIRS-IVUS were performed under hepa-
rin anticoagulation (activated clotting time > 300 s) 
following intracoronary nitroglycerine (100–200 µm) 
administration. 
NIRS-IVUS and OCT images were analyzed by 
the independent Core Laboratory (KCRI.org). Also, 
angiographic quantitative coronary analysis (QCA) 
was performed. Coronary lesions with incomplete 
and/or poor quality NIRS-IVUS or OCT scans 
were removed from the investigation (4 coronary 
lesions). Hence the ultimate analysis included 
14 coronary lesions assessed in 13 patients. 
The study was approved by to Local Bioethi-
cal Committee of Wroclaw Medical University in 
Poland, and all patients signed an informed consent 
before the procedure. 
QCA measurements
Quantitative coronary analysis was performed 
offline using a validated CAAS QCA software 
(Pie Medical Imaging BV) for calculation of mini-
mum lumen diameter and reference lumen diam-
eter (the average of the reference lumen diameter 
proximal to the lesion and reference lumen diam-
eter distal to the lesion). These data were used 
to calculate % diameter stenosis [(minimal lumen 
diameter/reference lumen diameter) × 100%]. 
Also, complete coronary segment morphology 
characteristics were evaluated according to the 
American Heart Association/American College of 
Cardiology classification.
FFR measurements
Fractional flow reverse measurements were 
performed using ILUMIEN™ OPTIS™ PCI Optimiza-
tion™ System (St. Jude Medical). The adenosine was 
applied intracoronary to a maximal dose of 140 µg for 
the left coronary artery and 100 µg for the right coro-
nary artery. All FFR measurements were performed 
after the intracoronary injection of nitroglycerine.
OCT image acquisition
The commercially available ILUMIEN™ 
OPTIS™ PCI Optimization™ System (St. Jude 
Medical) was used for OCT image acquisition. 
The tip of the 2.7 Fr. OCT catheter was placed at 
least 15 mm distally to the imaging target lesion. 
OCT image acquisition was then performed by 
the hand injection of  contrast (Visipaque; total 
volume 12–20 mL) and simultaneous OCT catheter 
pullback at 20 mm/s. Each OCT catheter pullback 
imaged a total of 54 mm of the vessel.
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OCT image analysis
Optical coherence tomography image analysis 
scrutinized serial cross-sectional images of the 
vessel, at 1 mm intervals, using the LightLab Im-
aging Offline Review Station. Plaque composition 
was analyzed according to previously validated cri-
teria for OCT [7]. In brief, signal rich homogenous 
plaques were classified as fibrous, signal-poor 
regions with diffuse borders were classified as lipid 
and signal-poor regions with well-defined borders 
were classified as calcified plaques. The magnitude 
of lipid content was measured as the circumferen-
tial extent of lipid in OCT cross-sectional images 
and expressed in degrees (OCT lipid arc,o).
When lipid arc was stretched > 90°, the OCT 
lipid-rich plaque was detected. Fibrous cap thick-
ness was derived by measuring the thinnest signal 
rich zone separating the lipid content from the 
vessel lumen (µm). The thinnest part of the fibrous 
cap was measured three times and its average was 
defined as the fibrous cap thickness. OCT-defined 
TCFA was defined as a lipid-rich plaque with fibrous 
cap thickness < 65 µm. Also, the presence of both 
plaque rupture and/or luminal thrombus was noted 
during OCT analysis.
The cross-sectional area (CSA),  minimumand 
maximum diameter of the vessel was measured 
every 1 mm. The smallest CSA in one segment 
was taken as the OCT-defined minimal CSA. The 
OCT reference lumen area was estimated as the 
largest CSA within 10 mm proximally or distally to 
the minimal lumen CSA in the scanned coronary 
segment. 
Combined NIRS and grey-scale  
IVUS image acquisition 
Combined NIRS and gray-scale IVUS image 
acquisition was performed using the commercially 
available TVC Imaging System™ with the 2.4 Fr. 
TVC Insight Catheter (InfraReDx). The tip of the 
TVC catheter was positioned at least 10 mm distal 
to the imaging target lesion. Subsequently, the 
automated pullback was started with at 0.5 mm/s 
(240 rotations/min) until the TVC catheter entered 
the guiding catheter. 
NIRS image analysis
The raw spectra of NIRS estimate the prob-
ability of the presence of an atherosclerotic lipid 
core and measurements are displayed as a chemo-
gram — a digit code NIRS map [6]. The NIRS map 
analysis allows calculation of lipid core burden 
index (LCBI) in 4 mm pullback compartments. 
NIRS map analysis was performed using QIVUS 
Medis software.
Gray-scale IVUS image analysis
Quantitative gray-scale IVUS measurements 
were performed every 1 mm in scanned coronary 
segments using QIVUS Medis software (2.1 ver-
sion). Cross-sectional images were quantified for 
lumen CSA, external elastic lamina (EEM) CSA, 
plaque and media CSA and plaque burden. Plaque 
and media CSA were calculated as the difference 
between EEM CSA and lumen CSA. Plaque burden 
was calculated as plaque and media CSA divided 
by EEM CSA × 100 (%) at the minimal CSA site. 
The IVUS reference lumen area was estimated 
as the largest CSA within 10 mm located proximally 
or distally to the minimal lumen CSA in one ana-
lyzed coronary segment. The reference EEM CSA 
was calculated as an average of the proximal and 
distal EEM CSA with the smallest plaque burden, 
but not higher than 50%. If either the proximally or 
distally evaluated plaque burden was ≥ 50%, then 
the proximal or distal EEM CSA with the least 
plaque burden served as reference.
A lesion was defined as the region between 
proximal and distal EEM reference sites or as the 
region between either proximal or distal EEM 
reference sites or a side branch delimiting the as-
sessed coronary segment. Remodeling index (RI) 
was calculated by dividing EEM CSA at the site 
of minimal lumen CSA by reference EEM CSA. 
Lesions with RI ≤ 0.95 were defined as negatively 
remodeled, while those with an RI ≥ 1.05 were 
defined as positively remodeled. An RI between 
these values was taken as a non-remodeled vessel.
In every lesion, a lumen vessel volume and 
EEM volume was calculated based on Simpson’s 
rule (mm3/cm). These data were used to estimate 
plaque volume (EEM volume – vessel volume, 
mm3/cm) and % plaque volume [100 × (plaque 
volume) / EEM volume, %].
Co-registration of NIRS, gray-scale  
IVUS and OCT
During the combined NIRS-IVUS pullback, 
anatomical landmarks were imprinted on the 
chemogram and bookmarked on  IVUS images — 
i.e. fiducial points, minimal vessel CSA and side 
branches. Those landmarks allowed matching of 
OCT images to corresponding sections of NIRS 
map, IVUS images, and the coronary angiogram. 
Such co-registration allowed simultaneous judg-
ment of LCBI values, IVUS measurements and 
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OCT analysis in the same lesion of the coronary 
vessel.
The identification of vulnerable lesions
According to the previously published studies, 
the following vulnerable lesions were identified by 
OCT and NIRS-IVUS imaging. OCT-defined TCFA 
as described above, IVUS vulnerable plaque de-
fined as lesion with PB > 70% and MLA < 4 mm2 
(PROSPECT study) [4], and NIRS-IVUS TCFA 
described previously as LCBI4 mm > 265 with simul-
taneous positive RI of the vessel [6] and lesions 
with LCBI4 mm > 400, which was the threshold of li-
pid burden for observed culprit STEMI lesions [8].
Statistical analysis
Kolmogorov-Smirnov analysis assessed the 
obtained data distribution. For normally distributed 
values data are presented as mean with standard 
deviation, for non-normally distributed values 
data were presented as median with interquartile 
intervals (IQR, 25 percentile, 75 percentile). Data 
analysis was performed using Medcalc software 
(16.8.4).
Results
Patient characteristics
There were 13 patients (8 male; 61%) with 
stable coronary artery disease enrolled into the 
study with a mean age 62.84 ± 6.03 years and 
with a mean body mass index 27.08 ± 2.42. Eleven 
(85%) patients suffered from hypertension, 6 (46%) 
had hyperlipidemia, 2 (15%) were diabetic, and 
7 (54%) were smokers. All patients received 
aspirin, 11 (85%) received thienopyridine. Both 
diabetic patients were using insulin injection. 
QCA analysis
The reference lumen diameter  was 2.9 (IQR 
2.29, 3.39) with MLD 1.44 (IQR 0.96, 1.96) and 
lesion length 7.06 mm (IQR 6.34, 12.64). The 
median % DS was 52% (IQR 33, 61). One lesion 
was classified as B2/C; the other 12 lesions were 
classified as A/B1.
FFR assessment
Two lesions were found to have FFR < 0.80 
(0.65 and 0.76). The other 11 lesions had mean 
FFR 0.88 ± 0.049. Two FFR positive lesions were 
located in the proximal and medial segment of 
the left anterior descending artery (LAD). FFR 
negative segments were located as follows: 4 in 
proximal LAD, 4 in medial LAD, 1 in distal left 
main, 1 in proximal right coronary artery and 1 in 
the ramus intermedius. Only FFR positive lesions 
were stented.
NIRS-IVUS imaging 
For the reference segment of the vessel, EEM 
CSA was 15.59 ± 6.81 mm2, lumen CSA was 7.11 ± 
± 3.10 mm2, plaque and media CSA was 8.48 ± 
± 3.98 mm2, and PB was 53.76 ± 7.69%.
For the minimum lumen site, the EEM CSA 
was 9.42 mm2 (IQR 7.48, 14.53), lumen CSA was 
2.75 mm2 (IQR 2.35, 4.47), plaque and media CSA 
was 6.78 mm2 (QR 5.02, 10.22), PB was 69.42% 
(IQR 63.92, 74.96). Plaque volume was 95.42 mm3 
(IQR 78.44, 104.28), vessel volume was 155.64 
mm3 (IQR 138.94, 194.01), plaque length was 
13.46 mm (IQR 7.56, 16.43) and median RI was 
1.27 (IQR 1.048, 1.50). Median maxLCBI4 mm was 
337 (IQR 162, 440).
OCT analysis
Median MLA was 2.62 (IQR 2.25, 4.29), me-
dian reference lumen area was 5.85 (IQR 5.49, 8.91) 
with % area stenosis 57% (IQR 48.65, 65.54). Nine 
(75%) lesions were calcified with median calcifica-
tion arc 114 (IQR 104, 153). Ten (83%) lesions were 
lipid-rich with median lipid arc 172 (IQR 112, 253). 
Median thickness of the fibrous cap covering the 
lipid core was 45 µm (IQR 40, 90). Eight lesions 
were classified as OCT defined-TCFA.
OCT and NIRS-IVUS imaging in detection 
of plaque vulnerability
Two lesions with FFR ≤ 0.80 had PB > 70% and 
MLA < 4 mm2, but none of these two lesions were 
identified as OCT defined TCFA or NIRS-IVUS pos-
sible TCFA. Among the other 11 lesions with FFR 
> 0.80, 8 were identified as OCT-defined TCFA, 
4 had a PB of more than 70%, 6 had MLA less than 
4 mm2, 2 had both PB > 70% and MLA < 4 mm2, 
3 were identified as NIRS-IVUS possible TCFA, and 
4 had LCBI > 400 mm (Table 1, Fig. 1).
Discussion
It remains challenging to identify vulnerable 
plaques which rupture and cause an acute coronary 
occlusion. Previous intravascular imaging studies 
focused on morphological patterns of atheroma 
to detect such lesions, but it did not translate to 
its identification on daily clinical practice. Fur-
thermore, the introduction of FFR assessment 
simplified the operator’s decision by providing 
a selection of lesions between those to treat and 
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those to be left untouched. Such an approach 
was strongly indicated by clinical results and 
significantly improved patient outcome [9, 10]. 
Nevertheless, it pushed aside  lesion morphology 
assessment, which identifies vulnerable plaques. 
The presented proof of concept study showed that 
some of FFR negative lesions still posed traits of 
vulnerability.
Ischemic lesions increase by 12 times the risk 
of death at 5 year follow-up [11], and  treatment of 
such lesion decreases MACE [12]. On the other 
hand, not only lesion functionality increases the 
risk of  future MACE, but lesion morphology as 
well. Analysis from the PROSPECT study showed 
that lesions with PB ≥ 70% and MLA ≤ 4 mm2 
increases 3 times the risk of MACE at 3.4 year 
follow-up, respectively [4]. The present observa-
tions suggested that despite FFR negative results 
such IVUS vulnerable lesions may  remain left 
untreated and thus, may pose a risk to patients. 
Fractional flow reverse positive lesions had 
more lipids [13], presented higher PB and smaller 
MLA [14]. Furthermore, the length of the plaque 
and its volume positively correlated with FFR 
results as well [15]. Alltogether this suggests that 
most of the vulnerable intermediate lesions are al-
ready treated based on FFR measurements anyway, 
but it should be noted that a high consternation 
of necrotic core was also observed in FFR nega-
tive lesions [14]. Clinical observations presented 
similar clinical outcomes for the coronary lesion 
discrimination by IVUS or FFR [16], despite the 
limited utility of IVUS measurements to guide 
intervention [17]. Similar clinical outcomes for 
IVUS and FFR guided interventions suggest that 
some of IVUS guided intervention were preformed 
in FFR-negative vulnerable lesions, which brought 
benefit to patients.
Previous OCT analysis presented that non-
culprit lesions exposed traits of plaque vulnerabil-
ity for both acute and stable patients with a higher 
prevalence of TCFA in obese patients [18, 19]. 
With the presented study we have also observed 
OCT-defined TCFA in FFR negative lesions. Such 
atheroma also prevailed in non-culprit lesions in 
STEMI patients [3] and was more frequently found 
in cadavers who died from myocardial infarction [2]. 
Interestingly, recent studies presented that mor-
phological characteristics of plaques assessed 
by OCT were not independently associated with 
Figure 1. Representative images of fractional flow reserve (FFR) negative lesion by optical coherence tomography 
(OCT), intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS); A. The angiography of the intermediate 
lesion located in the proximal segment of the left descending artery with FFR = 0.87; B. OCT presents thin fibrous cap 
atheroma (white arrow) with minimal lumen are (MLA) = 2.7 m2; C. A combined NIRS-IVUS image presents MLA = 3.6 
mm2 with plaque burden = 71%; D. NIRS map presents the maximal lipid core burden index in 4 mm (LCBI) = 511.
Table 1. Comparison of FFR, OCT and NIRS-IVUS imaging and the identification of vulnerable lesion.
OCT defined 
TCFA
PB  
> 70%
MLA-IVUS  
< 4 mm2
PB > 70% 
and MLA  
< 4 mm2
NIRS-IVUS 
TCFA
LCBI4 mm 
> 400
FFR > 0.80 (n = 11) 8 (62%) 4 (31%) 6 (46%) 2 (15%) 3 (31%) 4 (36%)
FFR £ 0.80 (n = 2) 0 (0%) 2 (15%) 2 (15%) 2 (15%) 0 (0%) 0 (0%)
FFR — fractional flow reserve; OCT — optical coherence tomography; TCFA — thin fibrous cap atheroma; PB — plaque burden; MLA — minimal 
lumen area; IVUS — intravascular ultrasound; NIRS — near-infrared spectroscopy; LCBI4 mm — maximal lipid core burden index in the 4 mm segment
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FFR [20]. The presented observation extended 
these observations and confirmed the presence 
of OCT-defined TCFA in FFR negative lesions. 
Therefore, the first prospective COMBINE study 
has been launched to detect whether OCT-defined 
TCFA observed in FFR negative lesions of diabetic 
patients increased the risk of future MACE [21].
Recently, the intravascular NIRS has been 
introduced into coronary artery assessment, which 
provides a very simple and quantitative analysis of 
lipid burden within the assessed lesions. The in 
vitro study suggested its potential to detect vulner-
able plaques [22]. Furthermore, clinical observa-
tion advocated that it might identify vulnerable 
plaques [6, 8] and patients at risk of MACE [5]. 
Previously NIRS presented a high lipid burden in 
non-culprit lesions, but the assessment of lesion 
morphology by NIRS against FFR lesion was not 
performed previously [23]. With the present study, 
it was shown that some of the FFR-negative lesions 
pose traits of vulnerability, as detected by LCBI 
alone or combined NIRS-IVUS analysis. 
This proof of concept study confirmed that 
3 leading intravascular modalities might detect 
different traits of vulnerability in FFR negative 
lesions, which warrants further observation as to 
whether such lesions requires intervention. The 
implantation of drug eluting stent into vulnerable 
lesions replaces the risk of plaque rupture with 
risk of in-stent restenosis. Therefore, the concept 
emerged that TCFA might be covered with biore-
sorbable vascular scaffold bioresorbable vascular 
scaffold to thicken the fibrous cap of the lipid-rich 
plaque and thus to prevent its future rupture [24], 
but the latest results on bioresorbable vascular 
scaffold implantation strongly suggestsrefraining 
from their reckless use. On the other hand, such le-
sions may be left untouched and treated conserva-
tively. The application of aggressive lipid-lowering 
therapy decreased lipid content within the plaque 
and decreased its vulnerability [25, 26].
Limitations of the study
It was an observational study involving 
a very small group of patients. Secondly, it mostly 
referred to FFR-negative lesions, which biased 
final observations. The lack of patient follow-up 
limits the strength of the results.
Conclusions
The FFR-negative lesions pose traits of vul-
nerability as assessed simultaneously by IVUS, 
OCT and NIRS imaging.
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